Synta Pharmaceuticals - Synta Pharmaceuticals - Early, but positive (as expected)
Jul 02nd 2012 - Edison Investment Research today published a report on Synta Pharmaceuticals entitled "Synta Pharmaceuticals - Early, But Positive (as Expected)". In summary, the report says:
Synta has disclosed the much-anticipated data that supported a decision to go ahead with the Phase III stage of its GALAXY study of ganetespib in second-line, non-small cell lung cancer (NSCLC). The data show encouraging signs of efficacy, including a 2.5- to 3-fold improvement in PFS in two subgroups of adenocarcinoma, namely those with mutant KRAS and with elevated LDH. Improvements were seen in PFS and OS (with separation of the Kaplan-Meier curves) in the all adenocarcinoma group, but not in non-adeno. However, the decision not to disclose the statistical data on these results, seemingly for good reasons, panicked the market.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
